Alector, Inc.ALEC

時価総額

$1.3億

PER

神経変性疾患治療薬の開発の有力企業。血液脳関門輸送のABC技術と毒性タンパク除去・蛋白補充を目指す候補薬群を展開。2024年1月19日の公募で7,110万ドル調達、AbbVieやGSKとの提携あり。米国拠点で臨床開発を推進。

	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-105	-190	-36	-133	-130	-119
Depreciation and amortization	4	6	6	6	6	5
Stock-based compensation	16	31	41	46	43	39
Amortization of premiums and accretion of discounts on marketable securities	5	-1	-2	1	15	14
Amortization Right Of Use Asset	2	1	2	3	3	3
Operating Lease, Impairment Loss	1	0	-	-	-	2
Loss from disposal of fixed assets	-	-	-	-	-0	-
Receivable from collaboration partner	-	-	7	-5	-3	-
Prepaid expenses and other current assets	2	4	-1	4	6	-6
Other assets	0	2	3	1	1	-3
Accounts payable	0	2	2	-1	-0	-1
Accrued liabilities and accrued clinical supply costs	9	12	2	-3	3	0
Payable to collaboration partner	-	-	-	-	8	-2
Deferred revenue	-21	-21	293	66	-67	-101
Refund liability to collaboration partner	-	-	-	-	25	46
Lease liabilities	1	-2	-4	-4	-5	-6
Other long-term liabilities	0	-0	-0	1	1	-0
Net cash used in operating activities	-99	-167	299	-20	-184	-230
Purchase of property and equipment	15	5	3	4	2	1
Purchase of marketable securities	530	507	343	557	552	468
Maturities of marketable securities	496	407	286	402	653	574
Sale of marketable securities	-	-	11	-	4	3
Net cash provided by (used in) investing activities	-49	-105	-50	-159	102	107
Proceeds from Stock Options Exercised	2	6	29	3	1	-
Proceeds from Stock Plans	1	1	2	1	1	1
Proceeds from Issuance of Common Stock Upon Public Offering Net of Issuance Costs	-	-	-	-	-	71
Proceeds from debt financing, net of discount and issuance costs	-	-	-	-	-	9
Net cash provided by financing activities	172	232	30	5	3	82
Net decrease in cash, cash equivalents, and restricted cash	24	-40	279	-175	-80	-41
Capital Expenditures Incurred but Not yet Paid	3	0	1	0	0	-